Tectonic Therapeutic, Inc. Common Stock (TECX) Stock Price
TECXStock
$20.65+17.00%52W
Market Cap$403.69M
P/E—
PEG Ratio—
Div yield—
Beta1.30
TECX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.96%
Price vs S&P 500 (4W)-21.13%
VGM Score48.84
TECX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.35 | -$1.18 | +12.92%(+$0.18) | |
| Q1 2026 | -$1.17 | -$1.34 | -14.90%(-$0.17) | |
| Q4 2025 | -$1.11 | -$1.03 | +7.56%(+$0.08) | |
| Q3 2025 | -$1.05 | -$1.02 | +2.59%(+$0.03) | |
| Q2 2025 | -$0.98 | -$1.07 | -9.00%(-$0.09) |
TECX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.31
4.31
4.31
4.31
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TECXTectonic Therapeutic, Inc. Common Stock | — | — | C | — | — | — | — | $20.65 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Tectonic Therapeutic, Inc. Common Stock
Tectonic Therapeutics is a biotechnology company discovering and developing therapeutic proteins and antibodies that modulate GPCR function. Using its proprietary GEODe platform, the company designs biologic medicines to treat serious diseases with limited or no existing therapeutic options. The pipeline includes TX2100, a GPCR antagonist for hereditary hemorrhagic telangiectasia and fibrosis, and a program for pulmonary hypertension.